Adoption of Lutetium- 177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020.

Luka FlegarSmita George ThodukaDamiano LibrizziMarkus LusterAristeidis ZacharisHendrik HeersNicole EisenmengerHojjat AhmadzadehfarMatthias EiberWolfgang WeberChrister GroebenJohannes Huber

Published in: European journal of nuclear medicine and molecular imaging (2023)

Lu-PSMA RLT has been rapidly increasing in Germany in the recent years providing an additional therapy option. This development is remarkable, because of outstanding formal EMA approval.

Keyphrases

pet ct
pet imaging
squamous cell carcinoma
small cell lung cancer
electronic health record
computed tomography
drug administration